Jiangsu Hualv Biological Technology Co.Ltd.
Jiangsu Chinagreen Biological Technology Group Co.,Ltd. engages in the research, development, factory cultivation, and sale of edible fungi in China. It offers Flammulina velutipes; Pleurotus eryngii, including white jade mushroom and oyster mushroom; and Maitake mushrooms. The company was founded in 2010 and is headquartered in Suqian, China.
Jiangsu Hualv Biological Technology Co.Ltd. (300970) - Total Liabilities
Latest total liabilities as of June 2025: CN¥780.86 Million CNY
Based on the latest financial reports, Jiangsu Hualv Biological Technology Co.Ltd. (300970) has total liabilities worth CN¥780.86 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Hualv Biological Technology Co.Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Jiangsu Hualv Biological Technology Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Hualv Biological Technology Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Jiangsu Hualv Biological Technology Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Porvair plc
PINK:PVARF
|
USA | $61.86 Million |
|
Anhui Shiny Electronic Technology Company Limited
SHE:300956
|
China | CN¥1.82 Billion |
|
Shandong Longda Meat Foodstuff Co Ltd
SHE:002726
|
China | CN¥4.02 Billion |
|
Texmaco Rail & Engineering Limited
NSE:TEXRAIL
|
India | ₹20.21 Billion |
|
Shenwu Energy Saving Co Ltd
SHE:000820
|
China | CN¥353.66 Million |
|
Ascopiave S.p.A
PINK:ASCOF
|
USA | $858.83 Million |
|
Perma-Fix Environmental Svcs Inc
NASDAQ:PESI
|
USA | $35.79 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Jiangsu Hualv Biological Technology Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Hualv Biological Technology Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Hualv Biological Technology Co.Ltd. (2019–2024)
The table below shows the annual total liabilities of Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥786.12 Million | +42.66% |
| 2023-12-31 | CN¥551.03 Million | +20.36% |
| 2022-12-31 | CN¥457.83 Million | +4.31% |
| 2021-12-31 | CN¥438.92 Million | +39.93% |
| 2020-12-31 | CN¥313.67 Million | +11.82% |
| 2019-12-31 | CN¥280.52 Million | -- |